You are here: Industry Insights > UC

News List

Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients PharmaSources
December 12, 2024
Everest Medicines today announced that the first prescription of VELSIPITY® (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau.
Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis drugs.com
January 19, 2022
Galapagos has obtained marketing authorization from the UK Medicines and Healthcare products Regulatory...
Galapagos reports early clinical results for SIK inhibitor pharmatimes
July 16, 2021
Galapagos has reported early results from three studies of its salt inducible kinase (SIK) 2/3 inhibitor GLPG3970, the first candidate from its portfolio of SIK inhibitor compounds.
Gilead gets US FDA Accelerated Approval for Trodelvy to treat metastatic urothelial cancer expresspharma
April 15, 2021
Gilead Sciences announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously ...
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma prnasia
January 25, 2021
Merck and Pfizer Inc. today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are ...
Takeda launches IBD medication Kynteles in India expresspharma
July 09, 2020
Used to treat Ulcerative Colitis and Crohn's Disease as well, the drug expands the company’s GI portfolio in the country.
Ulcerative Colitis Outcomes Similar for Smokers, Nonsmokers drugs
August 12, 2019
Smokers and nonsmokers with ulcerative colitis (UC) have similar outcomes, according to a study published online in Alimentary Pharmacology and Therapeutics.
Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate pharmafocusasia
December 19, 2018
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with ....
Regentys Corporation Receives European Patent Approval for ECMH americanpharmaceuticalreview
December 17, 2018
Generex Biotechnology announced Regentys Corporation was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.”
Takeda bags Japan's approval for ulcerative colitis drug biospectrumasia
July 09, 2018
Entyvio was approved in the European Union and the U.S. in May 2014 for the treatment of adults with moderately to severely active UC

Previous page 1 2 Next page